secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001628280-23-017206
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook
--------------------------------------------------------------------------------

- Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.
- Gross margin 59.9%; SG&A as % of sales improved to 34.9% from 47.7%.
- Net loss $1.9M ($0.03 EPS) vs $7.7M ($0.11 EPS) in Q1 2022; Adjusted EBITDA loss only $0.1M.
- Raised conservative end of 2023 revenue outlook to 12.5% growth; generated $2.8M positive operating cash flow.
- Operating expenses reduced $2.8M (-15%) driven by lower legal, share-based comp, and severance costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/0001628280-23-017206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/cdxc-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer